STOCK TITAN
  1. Home
  2. News
  3. DRTS

Alpha Tau Medical Ltd - DRTS STOCK NEWS

Welcome to our dedicated news page for Alpha Tau Medical (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Tau Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Tau Medical's position in the market.

News
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
Rhea-AI Summary
Alpha Tau Medical announces CFO Raphi Levy's presentation at the Jefferies Radiopharma Innovation Summit on April 11th, 2024, to provide a corporate overview and update on Alpha DaRT™, the innovative alpha-radiation cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences
-
News
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Alpha Tau Medical Ltd. reported positive interim safety and feasibility data from a pancreatic cancer study in Montreal, entered a pivotal U.S. trial, submitted a PMDA application in Japan, and expanded its U.S. facility. The company has a strong financial position with $84.9 million in cash, providing a runway for at least two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
earnings
-
News
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS) will participate in the Barclays 26th Annual Global Healthcare Conference to showcase its innovative alpha-radiation cancer therapy Alpha DaRT™ on March 12th and 13th, 2024, in Miami, FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
conferences
News
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced Chairman and CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The Company will also be featured at the Biotech Showcase occurring in parallel, with plans to present on January 8, 2024. Alpha Tau has achieved highly promising interim results from the pancreatic cancer safety and feasibility trial, along with robust long-term data analyzed across four clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences
-
News
Alpha Tau to Participate in Sidoti Small-Cap Conference
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) will present at the Sidoti Small-Cap Virtual Conference on December 7th, 2023, to showcase their innovative alpha-radiation cancer therapy Alpha DaRT™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
News
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
Rhea-AI Summary
Alpha Tau Medical Ltd. (DRTS) announced interim results from the treatment of the first five patients in the safety and feasibility trial using Alpha DaRT to treat advanced pancreatic cancer. The data showed successful delivery in all cases, with no product-related Serious Adverse Events. The first five patients received conservative partial tumor coverage, and increased tumor responses were observed in patients with higher radium-224 levels. The CEO expressed optimism about the results exceeding expectations. The principal investigator noted the ease of use and accuracy in delivering Alpha DaRT sources into the pancreas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
News
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) and HekaBio K.K. announced that Japan’s Pharmaceuticals and Medical Devices Agency has accepted Alpha Tau’s submission for pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer. This submission is based on clinical trial results that exceeded safety and efficacy endpoints, with discussions underway for a potential commercial partnership in Japan. CEO Uzi Sofer highlighted the strategic importance of Japan as a market, while CEO Rob Claar emphasized the potential impact on patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
News
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reported treating the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel. They also provided an update on safety and feasibility trials, financial results, and corporate highlights. Former U.S. FDA Commissioner, Stephen M. Hahn, M.D. has been appointed to Alpha Tau Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
earnings
-
News
Alpha Tau to Participate in November Investor Conferences
Rhea-AI Summary
Alpha Tau Medical Ltd. announced that it will participate in several investor conferences in November 2023, including the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
News
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
Rhea-AI Summary
Alpha Tau Medical Ltd. has entered into a long-term lease agreement for a standalone building in Hudson, New Hampshire, to establish its second U.S. manufacturing site. The new site will be larger than the existing site in Lawrence, Massachusetts, and is expected to support the company's goals of scaling up capacity and achieving manufacturing redundancy. The company plans to initiate manufacturing of Alpha DaRT treatments at the Hudson facility within two years, with a capacity of nearly 1.8 million Alpha DaRT sources per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
Stock DRTS logo
Alpha Tau Medical Ltd

Nasdaq:DRTS

DRTS Rankings

#3802 Ranked by Market Cap
#3415 Ranked by Stock Gains
N/A Ranked by Dividends

DRTS Stock Data

196.47M
51.74M
25.72%
2.74%
0.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Jerusalem

About DRTS

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.